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Myocardial Recovery in Ambulatory Heart Failure Patients Treated with the
C-Pulse Cardiac Assist System: A Single Center Experience
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Michael Borkon1
1Saint Luke’s Mid America Heart Institute, Kansas City, MO
Background: The C-Pulse System is an implantable, non-blood contacting device
designed to provide long-term counterpulsation therapy for patients with
advanced heart failure. Results from a recently completed a 20 patient IDE
prospective study demonstrated improvements in NYHA class and quality of life
with a low incidence of adverse events. We describe our single center experience
in a subgroup of patients undergoing implantation of the C-pulse system who
showed signs of myocardial recovery allowing for successful discontinuation of
device support.
Methods: Between July 2010 and April 2012, six patients underwent implantation
of the C-Pulse device at a single institution under the feasibility study. Safety
endpoints included death, aortic disruption, neurologic events, myocardial infarc-
tion, and major infection at 6 months. Quality of life was assessed using the
MLWHF and the KCCQ.
Results: Mean age was 50 years (range 34-71) and 83% were male. All patients
were NYHA class III at baseline, with non-ischemic etiology in 83% (5/6). Two
patients were inotrope dependent. There were no deaths, no neurologic events,
aortic disruptions, myocardial infarctions, or mediastinal infections. One patient
was transitioned to an implantable LVAD at 97 days post implant for worsening
heart failure symptoms. Two patients remain clinically stable on device support
(1178 and 982 days). Three patients showed clinically signiﬁcant improvement
allowing for discontinuation of device support with explantation of the percu-
taneous lead (mean duration of support 659 days, range 534-793 days). In the
patients weaned, mean ejection fraction increased from 18.3% to 29.3% with a
mean reduction in LVEDD of 1.1cm. Mean follow up time post-weaning was 335
days (range 52-565 days). There have been no readmissions for recurrent heart
failure.
Conclusions: Long-term counterpulsation therapy with the C-pulse system has shown
feasibility, preliminary safety and efﬁcacy in patients with moderate to severe
ambulatory heart failure, with the potential for sufﬁcient myocardial recovery to allow
for discontinuance of device support in a signiﬁcant number of patients in our single
center experience.
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Background: The MitraSpacer (Cardiosolutions, Inc.) is a novel approach to
address mitral regurgitation by introducing a dynamic spacer with characteristics
that constantly adjust to the instantaneous hemodynamics of the mitral apparatus and
left atrium (LA). The purpose of this study was to evaluate the safety of the
MitraSpacer within the mitral valve apparatus in the Yucatan miniature swine
model.
Methods: Four (4) Yucatan miniature swine were enrolled in this study. Through a
left thoracotomy, the shaft of the MitraSpacer was introduced into the left ven-
tricular (LV) apex and advanced in to the LA avoiding the chordae tendineae. Once
the device was in place, the balloon was partially ﬁlled to the desired volume with an
iopromide/saline mix introduced by a subcutaneous access port. After implantation, all
animals were survived up to 90 days.
Results: Following implantation, device performance was assessed by ﬂuoroscopy
and echocardiography. The volume within the balloon shifted during the cardiac cycle
in all cases following the direction of blood ﬂow and applied pressure. All enrolled
animals survived up to 90 days for terminal imaging and tissue harvest. Echocar-
diographic data showed no change in LV ejection fraction from baseline to 90 days,
61.251.7% and 58.093.6% (p¼0.2) respectively, and slight changes in LA and LV
volumes consistent with the rate of growth of the animal over time. Cardiac perfor-
mance was maintained and no functional or structural changes to the mitral apparatus
were observed over 90 days by serial imaging. In addition, there were no observations
of disruption in LV diastolic function, pulmonary vein inﬂow, or tricuspid
regurgitation.
Conclusions: In a healthy porcine model, the feasibility of chronic (up to 90 days)
placement of the MitraSpacer was demonstrated. In contrast to currently used
mitral valve repair/replacement devices, the subcutaneous port of this device
allows for post-implantation adjustment of the balloon volume, making it poten-
tially ideal for treatment of patients with mitral regurgitation due to left ventricular
dysfunction.B24 JACC Vol 64/11/Suppl BTCT-81
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Background: Commercially available in-vitro cardiac simulators offer testing op-
portunities for transcatheter valve therapies (TVT) as they are able to replicate the
physiological ﬂow and pressure accurately. These simulators lack the anatomical
similarity needed for some transcatheter device testing as well as training and teaching
physicians. The ex-vivo simulator combines the anatomical similarity with physio-
logical ﬂow and pressure signatures.
Methods: The left side of a porcine heart was incorporated into a circulatory loop and
driven by a pulsatile pump. Compliances were added to achieve physiological pressure
and ﬂow signatures and native movement of the mitral (MV) and aortic (AV) heart
valve. Pressure transducers acquire the aortic, ventricular and mitral real-time pres-
sures. A ﬂow meter measures the cardiac output of the simulator. Access sites at aorta,
atrium and apex allow the insertion of TVT devices as well as endoscopic visualization.
Results: The pressure differences over the MV and AV are comparable to physio-
logical values. The characteristics of the valves such as oriﬁce area as well as the
duration of opening and closing comply with those in native hearts.Conclusions: The ex-vivo simulator reliably duplicates the movement of the MV and
AV. Hence it is a cost-effective, and user-centric bench top model suitable for testing
TVT and training and teaching of TVT methods. Advantages are the time associated
with each trial especially in comparison with animal tests and the low experimental
costs while still being able to test in an intact heart.
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Background: Surgical ventricular reconstruction has been used to treat heart failure
patients with large ventricular aneurysms. This study assessed the feasibility and ef-
ﬁcacy of performing minimally invasive thoracoscopically assisted transcatheter
ventricular restoration (TCVR) in an anteroseptal ovine infarction model.
Methods: Anteroseptal scar was achieved by percutaneous coil-occlusion of the left
anterior descending artery. Two months after occlusion, TCVR was performed in ﬁve
sheep via a minimal left thoracotomy and right external jugular catheter intervention.
Under endoscopic and ﬂuoroscopic guidance, trans-interventricular septal puncture
was performed at the epicardial border of the scar using a proprietary needle, and a
guidewire was externalized via a snare placed in the right ventricle from the right
external jugular vein. An internal anchor with a tether was inserted over the wire and
positioned on the right ventricular septum and an external anchor was deployed on the
LV anterior epicardium. Serial pairs of anchors were placed and LV walls were pli-
cated to completely exclude the scar through apposition of the antero-lateral wall to
the septum and exclusion of the intervening wall segment. LV performance was
evaluated before (baseline) and six weeks after device implantation by echo.
Results: All animals survived with no procedural or device-related complications.
Compared to baseline, LV end-systolic volume was decreased by 46% (34.016.8 vs.
baseline 62.020.9ml, p< 0.001) and end-diastolic volume decreased by 32%
(60.918.3 vs. baseline 89.518.0, p< 0.01) 6 weeks post TCVR. Ejection fraction
was signiﬁcantly increased by 14% (469% vs. baseline 329%, p< 0.01) and stroke
volume was preserved (26.93.9 vs. baseline 27.54.6ml, p¼NS).
Conclusions: A thoracoscopically assisted TCVR procedure is safe and effective. A
signiﬁcant and presumably clinically important reduction in LV volume can bej September 13–17, 2014 j TCT Abstracts/Heart Failure Therapies
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMachieved at the expense of radius, and therefore, wall tension, in the ovine model with
induced ischemic cardiomyopathy.
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What Amount of Intravenous Fluid Produces Maximum Hemodynamic Beneﬁt
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Background: In patients of tamponade, interim measures may occasionally be needed
when facilities for pericardial ﬂuid drainage are not immediately available. Intravas-
cular volume expansion is the most commonly advocated measure but with limited
scientiﬁc data.This study was undertaken to ascertain an optimum amount of ﬂuid that
can produce the maximum beneﬁt in tamponade patients.
Methods: Patients  16 years of age with large circumferential pericardial effusion,
and showing echocardiographic evidence of cardiac tamponade were included. He-
modynamically unstable patients; those with structural heart diseases; pregnant fe-
males and those undergoing hemodialysis were excluded. SBP and CO were measured
using Edwards Life Sciences Vigilance II monitor , Swan Ganz CCO catheter and
arterial access; at baseline and after each 250 ml of ﬂuid over 5 min (totalling to 1000
mL in 20 min). The entire ﬂuid was drained at the end of the procedure.
Results: A total of 28 patients constituted the study group; all of whom exhibited an
improvement in hemodynamic parameters (SBP, CO) with volume expansion. Sig-
niﬁcant (p< 0.05 ) increase in SBP, DBP, CO and CI values occurred upto 250-500 ml
bracket; above which the signiﬁcance was lost.
Conclusions: Rapid infusion of as little as 250 ml of intravenous normal saline may
improve the cardiac hemodynamics in a signiﬁcant proportion of tamponade patients.Angiography and QCA
Washington Convention Center, Lower Level, Hall A
Saturday, September 13, 2014, 5:00 PM–7:00 PM
Abstract nos: 84-93
TCT-84
Prospective, Online, Interactive Survey Comparing Visual Lesion Estimation To
Quantitative Coronary Angiography
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Background: Inaccurate lesion measurement and inappropriate stent length selection
can negatively affect clinical outcomes following coronary stent deployment. Mea-
surement errors resulting in longitudinal geographic miss or the use of inappropriately
long stents have been associated with restenosis and the need for target lesion
revascularization. This study evaluated interventional cardiologists’ (IC) ability to
measure lesions and select stent lengths.
Methods: This evaluationwas conducted as a prospective, online, interactive survey of 25
matched orthogonal angiographic images that were pre-scored using quantitative coronary
angiography (QCA). Participants provided estimates of lesion length and stent length se-
lection. These estimates were compared to the maximum QCA value. A 2-4 mm stent
overlap of both the proximal and distal lesion edgeswas considered to be optimal. Basedon
this, lesion lengths measurements>1 mm below and>4 mm above and stent lengths that
were less than4mmand>8mmfrom theQCAvaluewere considered to be short and long,
respectively. Five of the 25 images were repeated to assess intra-rater variability.
Results: Forty ICs participated. The results are summarized in Table 1. Accurate lesion
length measurement and stent length selection occurred in only 30.4% and 22.3% of
the cases, respectively. Stent length misses that would fail to cover the entire lesion
comprised 23.8% of the cases. Analysis of repeated images showed a>3mm difference
in 38.5% and 37.5% of length measurements and stent length selections, respectively.Table 1. Evaluator Lesion Length Measurement and Stent Length Selection
Relative to QCA
Short Accurate Long
Lesion Length Measurement 409 (51.1%) 243 (30.4%) 152 (19.0%)
47.6%, 54.6% 27.2%, 33.7% 16.3%, 21.9%
Stent Length Selection 440 (55.0%) 178 (22.3%) 182 (22.8%)
51.5%, 58.5% 19.4%, 25.3% 19.9%, 25.8%
N (percent of total)
95% conﬁdence interval
JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AngiograpConclusions: Manual assessment of the coronary lesion length has a high degree of
inter-rater and intra-rater variability, which may lead to inadequate stent selection and
lesion treatment. Employing methodology to improve the accuracy of lesion mea-
surement may improve patient outcomes.
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Arteries
Masahiko Shibuya1, Carlos A. Gongora1, Yanping Cheng1, Gerard B. Conditt1,
Jenn McGregor1, Juan Granada1, Greg L. Kaluza1
1Cardiovascular Research Foundation, Orangeburg, NY
Background: Stent underexpansion and malapposition continue to be important
factors in suboptimal outcomes of stent treatment of obstructive coronary disease. It is
well established that stents rarely achieve intended post-implant diameters that would
be expected from the maximum applied pressure and the stent pressure-diameter
characteristics provided by the manufacturer. In human arteries, the restrictive forces
preventing the stent from fully expanding are attributed to the rigidity and heteroge-
neous composition of atherosclerotically damaged wall, calciﬁcations in particular.
We sought to examine the true in-vivo stent recoil in response to elastic forces posed
by healthy porcine arteries.
Methods: One hundred ﬁfty eight stents were implanted in coronary arteries in
swine model aiming at an 120% overstretch ratio. Final minimum stent diameter
(MSD) immediately post-deployment was measured by QCA (XIENCE¼39,
RESOLUTE¼41, OMEGA¼42), intravascular ultrasound (IVUS) (LIBERTE ¼23,
PROMUS ¼16) and optical coherence tomography (OCT) (XIENCE¼12). In 122
stents examined by QCA, minimum balloon diameter (MBD) during stent
deployment was also measured. For each stent, MSD was compared to the projected
diameter (PD) that the stent was to achieve per compliance chart at the pressure
used.
Results: The average MSD by QCA was 7.98.3% lower than the PD expected
from the compliance chart at the pressure used. IVUS and OCT demonstrated
similar deﬁcit of MSD in comparison to PD (7.15.7% by IVUS and 9.44.8% by
OCT). MBD was only 2.56.4% lower than PD, thus accounting for w1/3 of the
deﬁcit, while w2/3 was due to true recoil. Stent type, coronary branch location
(RCA, LAD or LCX), baseline artery size (reference diameter), tapering of the
stented segment and the actual overstretch ratio had no evident impact on the
magnitude of deﬁcit/recoil.
Conclusions: Elastic resistance of normal porcine coronary arteries is sufﬁcient to
induce acute stent recoil signiﬁcantly beyond the typical manufacturer’s claim of less
than 3% based on bench testing in air with no external resistance. As a consequence,
stents consistently achieve 7-10 % less than the predicted diameter, even in complete
absence of atherosclerosis.
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Background: The extent of coronary artery disease (CAD), as quantiﬁed by the
baseline SYNTAX Score (bSS) and the residual SS (rSS) after PCI, have been shown
to be associated with adverse ischemic outcomes in various studies. We sought to
quantify the proportion of CAD burden treated by PCI and to evaluate its impact on 1-
year adverse ischemic events, using a newly developed index (the SYNTAX
Revascularization Index; SRI).
Methods: The bSS and rSS from 2,681 angiograms from patients enrolled in the
prospective ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy)
trial were determined. The SRI was then calculated for each patient by the following
formula [1-(rSS/bSS)] x 100. Patients were then stratiﬁed and outcomes examined
according to the proportion of revascularized myocardium (SRI¼100% (complete
revascularization), 50-99% and < 50%).
Results: The mean bSS was 12.8  6.7, and after PCI the mean rSS was 5.6  2.2.
The SRI was 100% in 1079 patients (40.2%) 50-99% in 908 patients (33.9%), and <
50% in 694 patients (25.9%). One-year adverse outcomes, including death, were
inversely proportional to the SRI (Table). By multivariable analysis, SRI was found to
be an independent predictor of 1-year mortality (hazard ratio (HR) ¼ 0.48 [95%CI
0.24, 0.95], P¼0.03). An SRI cutoff of < 80% (present in 1287 (48.0%) of patients
after PCI) had the best prognostic accuracy for risk prediction of death (AUC 0.60,
[95%CI 0.53, 0.67] p¼0.004).hy and QCA B25
